©2010 Baishideng. All rights reserved.
Presence of hepcidin-25 in biological fluids: Bile, ascitic and pleural fluids
Jayantha Arnold, Arvind Sangwaiya, Vijay Manglam, Department of Gastroenterology, Ealing Hospital NHS Trust, Uxbridge Road, London UB1 3HW, United Kingdom
Frank Geoghegan, Department of Biochemistry, Ealing Hospital NHS Trust, Uxbridge Road, London UB1 3HW, United Kingdom
Mark Thursz, Department of Hepatology, St Mary’s Hospital NHS Trust, Imperial College, Praed Street, London W2 1NY, United Kingdom
Mark Busbridge, Department of Clinical Chemistry, Charing Cross and Hammersmith Hospital NHS Trust, Imperial College, Fulham Palace Road, London W6 8RF, United Kingdom
Author contributions: Arnold J designed, supervised, co-authored and proof read the manuscript; Sangwaiya A designed, led laboratory work, wrote the paper and edited the manuscript; Manglam V recruited the patients, participated in research and helped write the manuscript; Geoghegan F helped in analysis of samples and co-authored the manuscript; Thursz M edited and proof read the manuscript; Busbridge M helped with laboratory work and help write the manuscript.
Supported by Grant from Ealing Hospital NHS Trust, Imperial College, United Kingdom
Correspondence to: Jayantha Arnold, Professor, Department of Gastroenterology, Ealing Hospital NHS Trust, Uxbridge Road, London UB1 3HW, United Kingdom. email@example.com
Telephone: +44-208-9675513 Fax: +44-208-9675083
Received: January 13, 2010
Revised: February 10, 2010
Accepted: February 17, 2010
Published online: May 7, 2010
AIM: To examine body fluids such as ascitic fluid (AF), saliva, bile and pleural effusions for the presence of hepcidin using a novel radioimmunoassay (RIA).
METHODS: Serum samples were collected from 25 healthy volunteers (mean age: 36 ± 11.9 years, 11 males, 14 females). In addition bile was obtained from 12 patients undergoing endoscopic retrograde cholangiopancreatography (mean age: 66.9 ± 16.7 years, M:F = 5:7). Saliva was collected from 17 healthy volunteers (mean age: 35 ± 9.9 years, M:F = 8:9). Pleural and AF were collected from 11 and 16 patients [(mean age: 72 ± 20.5 years, M:F = 7:4) and (mean age: 67.32 ± 15.2 years, M:F = 12:4)], respectively. All biological fluid samples (serum, exudative and transudative fluids) were tested for the presence of hepcidin-25 molecule using RIA.
RESULTS: Hepcidin-25 was detected in all biological fluids tested. The mean ± SD hepcidin-25 in serum was 15.68 ± 15.7 ng/mL, bile 7.37 ± 7.4 ng/mL, saliva 3.4 ± 2.8 ng/mL, exudative fluid 65.64 ± 96.82 ng/mL and transudative fluid 14.1 ± 17.8 ng/mL.
CONCLUSION: We provide clear evidence that hepcidin-25 is present in bile, saliva, pleural and ascitic fluids. Hepcidin is likely to play a role here in innate immunity.